EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis

Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Barbara Lins Silva, Ana Laura Soares Silva, Stellanny Cilene Rodrigues Castro, Michele Kreuz, Lilianne Rodrigues Fernandes, Francinny Alves Kelly, Rommel Mario Rodríguez Burbano

Journal of Gastrointestinal Cancer · 2025-12 · 56 (1)

DOI: 10.1007/s12029-024-01141-4 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 20.01.2025. Verfasst von Francisco Cezar Aquino de Moraes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Pará, R. Augusto Corrêa, GuamáBelem, Pará, nº0166073-005, Brazil. francisco.cezar2205@gmail.com. Hauptthemen laut MEDLINE: Stomach Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Gastric cancer (GC) remains a leading cause of morbidity and mortality worldwide. The current standard of care involves neoadjuvant chemotherapy (NACT) followed by radical gastrectomy. This study aims to evaluate the efficacy of neoadjuvant therapy with PD-1/PD-L1 inhibitors in comparison to chemotherapy alone for patients with locally advanced gastric cancer (LAGC). METHODS: We conducted a systematic search of PubMed, Web of Science, and Embase to identify studies examining the addition of PD-1/PD-L1 inhibitors to neoadjuvant therapy for LAGC. Odds ratios (OR) were calculated for binary outcomes, such as pathological complete response (pCR), with corresponding 95% confidence intervals (CI). RESULTS: Seven studies were included, encompassing a total of 1772 patients. Baseline median age ranged from 31 to 75 years. Most patients had an ECOG performance status score of 0 (942 patients), while 294 had an ECOG score of 1. The estimated pCR (OR 5.94, 95% CI 3.98-8.87; p < 0.000001) significantly favored the PD-1/PD-L1 inhibitors combined with chemotherapy over chemotherapy alone. Additionally, the incidence of certain adverse events increased significantly in the intervention group, including any-grade hypothyroidism (OR 4.55, 95% CI 2.27-9.10; p = 0.000019) and rash (OR 1.74, 95% CI 1.10-2.76; p = 0.017). Conversely, the control group showed a statistically significant lower incidence of grade ≥ 3 fatigue (OR 2.80, 95% CI 1.15-6.85; p = 0.024) compared to the intervention group. CONCLUSION: This systematic review and meta-analysis indicate that the addition of PD-1/PD-L1 inhibitors to neoadjuvant chemotherapy is associated with a higher pathological complete response rate compared to chemotherapy alone in patients with locally advanced gastric cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorAntineoplastic Combined Chemotherapy ProtocolsHumansNeoadjuvant TherapyGastrectomyAged

Stichwörter der Autor:innen

Advanced gastric cancerAnti-PD-1/PD-L1Meta-analysisNeoadjuvant

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Federal University of Pará, R. Augusto Corrêa, GuamáBelem, Pará, nº0166073-005, Brazil. francisco.cezar2205@gmail.com.
  • Federal University of Acre, Rio Branco, Acre, 69920-900, Brazil.
  • Vancouver Island Health Authority, 1947 Cook St, Victoria, BC, V8T 3P7, Canada.
  • Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, 38025-180, Brazil.
  • Federal University of Pará, R. Augusto Corrêa, GuamáBelem, Pará, nº0166073-005, Brazil.
  • Lutheran University of Brazil, Rio Grande Do Sul, Canoas, 92425-020, Brazil.

Zitieren

APA

de Moraes, F. C. A., Sano, V. K. T., Silva, B. L., Silva, A. L. S., Castro, S. C. R., Kreuz, M., Fernandes, L. R., Kelly, F. A., & Burbano, R. M. R. (2025). PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis. Journal of Gastrointestinal Cancer, 56(1). https://doi.org/10.1007/s12029-024-01141-4

Vancouver

de Moraes FCA, Sano VKT, Silva BL, Silva ALS, Castro SCR, Kreuz M, et al. PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis. Journal of Gastrointestinal Cancer. 2025;56(1). doi:10.1007/s12029-024-01141-4

BibTeX
@article{deMoraes2025,
  author = {de Moraes, Francisco Cezar Aquino and Sano, Vitor Kendi Tsuchiya and Silva, Barbara Lins and Silva, Ana Laura Soares and Castro, Stellanny Cilene Rodrigues and Kreuz, Michele and Fernandes, Lilianne Rodrigues and Kelly, Francinny Alves and Burbano, Rommel Mario Rodríguez},
  title = {PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2025},
  volume = {56},
  number = {1},
  doi = {10.1007/s12029-024-01141-4}
}
Kostenlos starten →